Abelacimab

Phase 3Monoclonal antibody

AAnthos Therapeutics, Inc.

Abelacimab is one of 27 biologic programs targeting Atrial Fibrillation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Atrial Fibrillation (AF)Recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Atrial Fibrillation (AF)Phase 3

Recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Abelacimab

AAnthos Therapeutics, Inc.

Phase 3

1 2

Rituxan

Xylocaine

1 4

Imbruvica

PPharmacyclics LLC.

Preclinical

1 5

Anticoagulants

Sanofi

Preclinical

2 6

Direct Anticoagulant

Bayer

Preclinical

1 7

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 8

Statin

Bristol-Myers Squibb

Preclinical

1 9

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 10

Magnesium SO4

HHospital de Base

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Genitourinary Cancer

NCT05171075

Q4 2027

Phase 3Recruiting

Atrial Fibrillation (AF)

NCT05712200

Q4 2028

Phase 2Active, not recruiting

Atrial Fibrillation

NCT04755283

Clinical

Trials by Indication[1]

Treatment1 trial

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Terminated·AAnthos Therapeutics, Inc.·Phase 3·NCT05171049·1,150 enrolled

Genitourinary Cancer1 trial

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Active, not recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05171075·417 enrolled

Atrial Fibrillation1 trial

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Active, not recruiting·AAnthos Therapeutics, Inc.·Phase 2·NCT04755283·1,287 enrolled

Atrial Fibrillation (AF)1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05712200·2,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Abelacimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abelacimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abelacimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anthos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAnthos Therapeutics, Inc.

Abelacimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Treatment1 trial

Genitourinary Cancer1 trial

Atrial Fibrillation1 trial

Atrial Fibrillation (AF)1 trial

References

Drug Info

Quick Facts

Related News